The CEO's $911K open-market sale without a disclosed 10b5-1 plan is the most significant signal in this cluster. Monitor for upcoming material news (e.g., clinical data, partnership, or financing) that may have prompted the sale. The derivative exercises and tax withholding are routine and do not alter the bearish read.
Price Chart
Executive Summary
Monopar Therapeutics insiders executed a cluster of non-cash derivative exercises and tax-withholding share surrenders on September 30, 2026, alongside open-market sales by the CEO ($911K) and a director ($362K) totaling $1.27M. The open-market sales represent approximately 0.39% of the company's $326M market cap, a modest but notable signal. The derivative exercises and tax-withholding transactions are routine and carry no economic signal.
Key Financial Metrics
Key Facts
- CEO Chandler sold 10,400 shares in an open-market sale for $911K on September 24, 2026.
- Director Starr sold 4,600 shares in an open-market sale for $362K on October 1, 2026.
- Total open-market sales: $1.27M, approximately 0.39% of market cap.
- CFO Vu, CEO Chandler, and COO Cittadine exercised derivative securities and surrendered shares for tax withholding on September 30, 2026 — non-cash transactions with no economic signal.
- No 10b5-1 plan indication was provided for the open-market sales.
Financial Impact
Open-market sales of $1.27M represent ~0.39% of market cap — modest but notable insider selling.
Risk Factors
- CEO selling $911K without a 10b5-1 plan may indicate negative private information.
- Director selling $362K shortly after CEO sale adds to the bearish signal.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MNPR-1791236638832 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 20d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $69.93 (+12.12%) |
Oct 1, 2026 24d ago | 144 | $77.97 | awaiting T+60 | — | $69.93 (−10.32%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $69.93 (−37.53%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $69.93 (−37.51%) |
Aug 25, 2026 8w ago | 144 | $113.72 | awaiting T+60 | — | $69.93 (−38.51%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $69.93 (−39.14%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $69.93 (−39.14%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $69.93 (−37.83%) |
Jul 22, 2026 13w ago | Press Release | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $69.93 (−37.83%) |
Jun 30, 2026 16w ago | 8-K | $92.59 $89.38 | ▼ −3.47% | ▼ −7.03% | $69.93 (−24.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers